

A Study of GensSci098 in Subjects With Graves' Disease

NCT07286656

Status	RECRUITING
Phase	Phase 1
Sponsor	Changchun GeneScience Pharmaceutical Co., Ltd.
Enrollment	24 participants

Key Eligibility Criteria

Inclusion (8)

- Age e 18 years.
 - Voluntary signed informed consent.
 - Confirmed diagnosis of diffuse toxic goiter (Graves' disease).
 - Abnormal thyroid function tests (e.g., elevated T4, and suppressed TSH).
 - No prior or recent use of antithyroid medications (discontinued for at least 4 weeks).
- ... and 3 more (see full listing online)

Exclusion (21)

- Non-diffuse toxic goiter-induced hyperthyroidism.
 - Previous radioactive iodine treatment or thyroid surgery.
 - History or risk of thyroid storm.
 - Use of thyroid hormone medications within the past 6 weeks.
 - accompanied by active thyroid eye disease.
- ... and 16 more (see full listing online)

Locations (1 total)

The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China